1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). Jama. 2016;315(8):801-10.
2. Fleischmann C, Thomas-Rueddel DO, Hartmann M, Hartog CS, Welte T, Heublein S, et al. Hospital Incidence and Mortality Rates of Sepsis. Deutsches Arzteblatt international. 2016;113(10):159-66.
3. Angus DC, van der Poll T. Severe sepsis and septic shock. The New England journal of medicine. 2013;369(9):840-51.
4. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive care medicine. 2017;43(3):304-77.
5. Steinhagen F, Schmidt SV, Schewe JC, Peukert K, Klinman DM, Bode C. Immunotherapy in sepsis - brake or accelerate? Pharmacology & therapeutics. 2020;208:107476.
6. David S, Stahl K. To remove and replace-a role for plasma exchange in counterbalancing the host response in sepsis. Critical care (London, England). 2019;23(1):14.
7. Stahl K, Bode C, David S. [Extracorporeal Strategies in Sepsis Treatment: Role of Therapeutic Plasma Exchange]. Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS. 2021;56(2):101-10.
8. Stahl K, Schmidt JJ, Seeliger B, Schmidt BMW, Welte T, Haller H, et al. Effect of therapeutic plasma exchange on endothelial activation and coagulation-related parameters in septic shock. Critical care (London, England). 2020;24(1):71.
9. Knaup H, Stahl K, Schmidt BMW, Idowu TO, Busch M, Wiesner O, et al. Early therapeutic plasma exchange in septic shock: a prospective open-label nonrandomized pilot study focusing on safety, hemodynamics, vascular barrier function, and biologic markers. Critical care (London, England). 2018;22(1):285.
10. Stahl K, Bikker R, Seeliger B, Schmidt JJ, Schenk H, Schmidt BMW, et al. Effect of Therapeutic Plasma Exchange on Immunoglobulin Deficiency in Early and Severe Septic Shock. Journal of intensive care medicine. 2020:885066620965169.
11. Rimmer E, Houston BL, Kumar A, Abou-Setta AM, Friesen C, Marshall JC, et al. The efficacy and safety of plasma exchange in patients with sepsis and septic shock: a systematic review and meta-analysis. Critical care (London, England). 2014;18(6):699.
12. Busund R, Koukline V, Utrobin U, Nedashkovsky E. Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial. Intensive care medicine. 2002;28(10):1434-9.
13. Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, Delaney M, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. Journal of clinical apheresis. 2016;31(3):149-62.
14. David S, Bode C, Putensen C, Welte T, Stahl K. Adjuvant therapeutic plasma exchange in septic shock. Intensive care medicine. 2021;47(3):352-4.
15. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive care medicine. 2013;39(2):165-228.
16. McIntosh AM, Tong S, Deakyne SJ, Davidson JA, Scott HF. Validation of the Vasoactive-Inotropic Score in Pediatric Sepsis. Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies. 2017;18(8):750-7.
17. Keith PD, Wells AH, Hodges J, Fast SH, Adams A, Scott LK. The therapeutic efficacy of adjunct therapeutic plasma exchange for septic shock with multiple organ failure: a single-center experience. Critical care (London, England). 2020;24(1):518.
18. Nylen ES, Whang KT, Snider RH, Jr., Steinwald PM, White JC, Becker KL. Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis. Critical care medicine. 1998;26(6):1001-6.
19. Becker KL, Snider R, Nylen ES. Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target. British journal of pharmacology. 2010;159(2):253-64.
20. Adamik B, Smiechowicz J, Jakubczyk D, Kübler A. Elevated Serum PCT in Septic Shock With Endotoxemia Is Associated With a Higher Mortality Rate. Medicine. 2015;94(27):e1085.
21. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. Jama. 2001;286(15):1869-78.
22. Hayakawa M, Kudo D, Saito S, Uchino S, Yamakawa K, Iizuka Y, et al. Antithrombin Supplementation and Mortality in Sepsis-Induced Disseminated Intravascular Coagulation: A Multicenter Retrospective Observational Study. Shock (Augusta, Ga). 2016;46(6):623-31.
23. Tagami T, Matsui H, Horiguchi H, Fushimi K, Yasunaga H. Antithrombin and mortality in severe pneumonia patients with sepsis-associated disseminated intravascular coagulation: an observational nationwide study. Journal of thrombosis and haemostasis : JTH. 2014;12(9):1470-9.
24. Wiedermann CJ, Hoffmann JN, Juers M, Ostermann H, Kienast J, Briegel J, et al. High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Critical care medicine. 2006;34(2):285-92.
25. Shorr AF, Bernard GR, Dhainaut JF, Russell JR, Macias WL, Nelson DR, et al. Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome. Critical care (London, England). 2006;10(3):R92.
26. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. The New England journal of medicine. 2001;344(10):699-709.
27. Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, et al. Drotrecogin alfa (activated) in adults with septic shock. The New England journal of medicine. 2012;366(22):2055-64.
28. Seymour CW, Kennedy JN, Wang S, Chang CH, Elliott CF, Xu Z, et al. Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis. Jama. 2019;321(20):2003-17.
29. Brunkhorst FM, Patchev V. [Sepsis-associated Purpura Fulminans International Registry--Europe (SAPFIRE)]. Medizinische Klinik, Intensivmedizin und Notfallmedizin. 2014;109(8):591-5.
30. Knoebl P, Schellongowski P, Staudinger T, Sperr WR, Scheibenpflug C. Treatment Of Infection-Associated Purpura Fulminans With Protein C Zymogen Is Associated With a High Survival Rate. Blood. 2013;122(21):3606-.
31. Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413(6855):488-94.
32. Aibar J, Castro P, Espinosa G, Fernández S, Hernández C, Rinaudo M, et al. ADAMTS-13 in Critically Ill Patients With Septic Syndromes and Noninfectious Systemic Inflammatory Response Syndrome. Shock (Augusta, Ga). 2015;43(6):556-62.
33. Bockmeyer CL, Claus RA, Budde U, Kentouche K, Schneppenheim R, Lösche W, et al. Inflammation-associated ADAMTS13 deficiency promotes formation of ultra-large von Willebrand factor. Haematologica. 2008;93(1):137-40.
34. Kremer Hovinga JA, Zeerleder S, Kessler P, Romani de Wit T, van Mourik JA, Hack CE, et al. ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock. Journal of thrombosis and haemostasis : JTH. 2007;5(11):2284-90.
35. Ono T, Mimuro J, Madoiwa S, Soejima K, Kashiwakura Y, Ishiwata A, et al. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood. 2006;107(2):528-34.
36. Peigne V, Azoulay E, Coquet I, Mariotte E, Darmon M, Legendre P, et al. The prognostic value of ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13) deficiency in septic shock patients involves interleukin-6 and is not dependent on disseminated intravascular coagulation. Critical care (London, England). 2013;17(6):R273.
37. Lin JJ, Chan OW, Hsiao HJ, Wang Y, Hsia SH, Chiu CH. Decreased ADAMTS 13 Activity is Associated With Disease Severity and Outcome in Pediatric Severe Sepsis. Medicine. 2016;95(16):e3374.
38. Claus RA, Bockmeyer CL, Budde U, Kentouche K, Sossdorf M, Hilberg T, et al. Variations in the ratio between von Willebrand factor and its cleaving protease during systemic inflammation and association with severity and prognosis of organ failure. Thrombosis and haemostasis. 2009;101(2):239-47.
39. Stiehl T, Thamm K, Kaufmann J, Schaeper U, Kirsch T, Haller H, et al. Lung-targeted RNA interference against angiopoietin-2 ameliorates multiple organ dysfunction and death in sepsis. Critical care medicine. 2014;42(10):e654-62.
40. David S, Mukherjee A, Ghosh CC, Yano M, Khankin EV, Wenger JB, et al. Angiopoietin-2 may contribute to multiple organ dysfunction and death in sepsis*. Critical care medicine. 2012;40(11):3034-41.
41. Kumpers P, Gueler F, David S, Slyke PV, Dumont DJ, Park JK, et al. The synthetic tie2 agonist peptide vasculotide protects against vascular leakage and reduces mortality in murine abdominal sepsis. Critical care (London, England). 2011;15(5):R261.
42. Kümpers P, Hafer C, David S, Hecker H, Lukasz A, Fliser D, et al. Angiopoietin-2 in patients requiring renal replacement therapy in the ICU: relation to acute kidney injury, multiple organ dysfunction syndrome and outcome. Intensive care medicine. 2010;36(3):462-70.
43. Alawo DOA, Tahir TA, Fischer M, Bates DG, Amirova SR, Brindle NPJ. Regulation of Angiopoietin Signalling by Soluble Tie2 Ectodomain and Engineered Ligand Trap. Scientific reports. 2017;7(1):3658.
44. Aydin K, Korkmaz S, Erkurt MA, Sarici A, Ekinci O, Baysal NA, et al. Apheresis in patients with sepsis: A multicenter retrospective study. Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis. 2021:103239.
45. Reeves JH, Butt WW, Shann F, Layton JE, Stewart A, Waring PM, et al. Continuous plasmafiltration in sepsis syndrome. Plasmafiltration in Sepsis Study Group. Critical care medicine. 1999;27(10):2096-104.
46. Nguyen TC, Han YY, Kiss JE, Hall MW, Hassett AC, Jaffe R, et al. Intensive plasma exchange increases a disintegrin and metalloprotease with thrombospondin motifs-13 activity and reverses organ dysfunction in children with thrombocytopenia-associated multiple organ failure. Critical care medicine. 2008;36(10):2878-87.
47. Long EJ, Taylor A, Delzoppo C, Shann F, Pearson G, Buckley D, et al. A randomised controlled trial of plasma filtration in severe paediatric sepsis. Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine. 2013;15(3):198-204.
48. Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. Journal of clinical apheresis. 2019;34(3):171-354.
49. Seeliger B, Stahl K, David S. [Extracorporeal techniques for blood purification in sepsis: an update]. Der Internist. 2020;61(10):1010-6.
50. Supady A, Weber E, Rieder M, Lother A, Niklaus T, Zahn T, et al. Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation (CYCOV): a single centre, open-label, randomised, controlled trial. The Lancet Respiratory medicine. 2021;9(7):755-62.
51. Wendel Garcia PD, Hilty MP, Held U, Kleinert EM, Maggiorini M. Cytokine adsorption in severe, refractory septic shock. Intensive care medicine. 2021:1-3.